Dengue – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) Market -
DENGUE PIPELINE ANALYSIS
• Dengue is a mosquito-borne infectious disease caused by the dengue virus, which is typically a single positive-stranded RNA virus.
• Dengue is transmitted through the bite of infected Aedes mosquito, mainly Aedes aegypti and Aedes albopictus. This can be transmitted through exposure to infected blood, organs, or other tissues.
• The Aedes aegypti mosquito is responsible for transmitting the dengue virus (DENV). The virus causing dengue belongs to the Flavivirus genus of the Flaviviridae family.
• Symptoms of dengue include a headache, fatigue, high fever, muscle pain, anemia, diarrhea, skin rashes, and vomiting.
• Severe dengue will cause seizures, yellow skin, coma, or death. Dengue causes CNS manifestations, which includes any degree of impaired consciousness, abnormal neurological signs, delirium, and focal and generalized convulsions.
• It can also cause dengue shock syndrome, which shows massive bleeding and shock. Dengue fever resembles influenza and affects adults, children, as well as infants, but it is rarely fatal. Treatment includes the use of analgesics, fluid replacement therapy, and a healthy lifestyle.
• Even though a vaccine for treating dengue is available now, which is a significant achievement, its long-term protective efficacy against 4-dengue virus serotypes also remains to be definitively determined.
• There are different causes underlying the clinical event of dengue for which multimodal and effective treatment approach is required. Among all the effective treatments available, vaccines are considered as the best available precaution option for dengue.
• Several vaccines currently under clinical trials are showing promising effects that include TVD, TV003, TV005, TVDV, and TDENV. Expected approval for the vaccine TV003 (by Butantan Institute.) a live attenuated vaccine is likely to drive the market in the next few years.
• In terms of product, the market has been categorized into only one product, i.e. CYD-TDV (Dengvaxia) as only one vaccine of Sanofi Pasteur is approved in the market.
• Drugs are a complementary intervention that may be useful for patients who contract dengue if they did not receive an approved vaccine for dengue or for whom vaccination was ineffective.
• These drugs are at various stages of clinical development. However, no antivirals have been developed exclusively for dengue has entered into the clinical trials. balapiravir is the only drug that is deemed to directly target one of the viral proteins (NS5) and has been clinically investigated.
• This nucleoside analog, developed by Roche Pharmaceutical for hepatitis C, was also examined as a short-course treatment against dengue because of its useful short-course safety profile.
• This compound, however, did not meet the efficacy endpoint, because of altered host cell kinase expression or activity during dengue infection.
• Although no antiviral agent has been found yet now to be effective against acute dengue in proof-of-concept trials, the therapeutic pipeline development still contains several compounds and biologics that will be soon clinically evaluated. Some of phase III clinical pipeline biologicals include tetravalent dengue vaccine (TDV), Yellow fever vaccine (YF-17D) developing by Takeda, CYD Dengue vaccine, HAV vaccine, Human Papillomavirus Bivalent vaccine are going to increase the future dengue market growth.
• Rising prevalence of diseases, increasing company initiatives to enhance R&D are driving the growth of the vaccines market, increasing government and non-government funding for vaccine development, and.
• On the other hand, market growth may be hampered due to the high cost of vaccine development. Raising awareness about symptoms of dengue fever and raising government initiatives to provide better healthcare facilities provides ample opportunities for the market growth.
• Rapid urbanization, lack of sanitation, increase in international trade and mobility of population restraint the efforts to control dengue.
• Dengue is a mosquito-borne infectious disease caused by the dengue virus, which is typically a single positive-stranded RNA virus.
• Dengue is transmitted through the bite of infected Aedes mosquito, mainly Aedes aegypti and Aedes albopictus. This can be transmitted through exposure to infected blood, organs, or other tissues.
• The Aedes aegypti mosquito is responsible for transmitting the dengue virus (DENV). The virus causing dengue belongs to the Flavivirus genus of the Flaviviridae family.
• Symptoms of dengue include a headache, fatigue, high fever, muscle pain, anemia, diarrhea, skin rashes, and vomiting.
• Severe dengue will cause seizures, yellow skin, coma, or death. Dengue causes CNS manifestations, which includes any degree of impaired consciousness, abnormal neurological signs, delirium, and focal and generalized convulsions.
• It can also cause dengue shock syndrome, which shows massive bleeding and shock. Dengue fever resembles influenza and affects adults, children, as well as infants, but it is rarely fatal. Treatment includes the use of analgesics, fluid replacement therapy, and a healthy lifestyle.
• Even though a vaccine for treating dengue is available now, which is a significant achievement, its long-term protective efficacy against 4-dengue virus serotypes also remains to be definitively determined.
• There are different causes underlying the clinical event of dengue for which multimodal and effective treatment approach is required. Among all the effective treatments available, vaccines are considered as the best available precaution option for dengue.
• Several vaccines currently under clinical trials are showing promising effects that include TVD, TV003, TV005, TVDV, and TDENV. Expected approval for the vaccine TV003 (by Butantan Institute.) a live attenuated vaccine is likely to drive the market in the next few years.
• In terms of product, the market has been categorized into only one product, i.e. CYD-TDV (Dengvaxia) as only one vaccine of Sanofi Pasteur is approved in the market.
• Drugs are a complementary intervention that may be useful for patients who contract dengue if they did not receive an approved vaccine for dengue or for whom vaccination was ineffective.
• These drugs are at various stages of clinical development. However, no antivirals have been developed exclusively for dengue has entered into the clinical trials. balapiravir is the only drug that is deemed to directly target one of the viral proteins (NS5) and has been clinically investigated.
• This nucleoside analog, developed by Roche Pharmaceutical for hepatitis C, was also examined as a short-course treatment against dengue because of its useful short-course safety profile.
• This compound, however, did not meet the efficacy endpoint, because of altered host cell kinase expression or activity during dengue infection.
• Although no antiviral agent has been found yet now to be effective against acute dengue in proof-of-concept trials, the therapeutic pipeline development still contains several compounds and biologics that will be soon clinically evaluated. Some of phase III clinical pipeline biologicals include tetravalent dengue vaccine (TDV), Yellow fever vaccine (YF-17D) developing by Takeda, CYD Dengue vaccine, HAV vaccine, Human Papillomavirus Bivalent vaccine are going to increase the future dengue market growth.
• Rising prevalence of diseases, increasing company initiatives to enhance R&D are driving the growth of the vaccines market, increasing government and non-government funding for vaccine development, and.
• On the other hand, market growth may be hampered due to the high cost of vaccine development. Raising awareness about symptoms of dengue fever and raising government initiatives to provide better healthcare facilities provides ample opportunities for the market growth.
• Rapid urbanization, lack of sanitation, increase in international trade and mobility of population restraint the efforts to control dengue.
